Title
The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: First-year results from the Compliance of ARomatase Inhibitors AssessmenT In Daily practice through Educational approach (CARIATIDE) study
Date Issued
01 January 2014
Access level
open access
Resource Type
journal article
Author(s)
Neven P.
Markopoulos C.
Tanner M.
Marty M.
Kreienberg R.
Atkins L.
Franquet A.
Gnant M.
Tesarova P.
Barni S.
Deschamp V.
Publisher(s)
Churchill Livingstone
Abstract
The CARIATIDE study was designed to assess the impact of educational materials (EMs) on compliance and persistence rates with aromatase inhibitor (AI) treatment in postmenopausal women with hormone-receptor-positive early breast cancer. Patients were randomized to standard AI treatment (Group A; N=1379) or standard AI treatment plus EMs containing information on a range of breast-cancer-related topics (Group B; N=1379). Standardized questionnaires assessed investigator-perceived levels of care and evaluated patient compliance and behavior. At 1 year, there was no significant difference in compliance between Group A and Group B (81% vs. 82%, p=0.4524). However, higher compliance in patients receiving EMs was observed in Sweden/Finland (p=0.0246). Compliance with initial AI and persistence rate were not significantly altered by EM. Other factors associated with improved compliance, irrespective of EMs, e.g. administration of chemotherapy were identified. © 2014 Elsevier Ltd.
Start page
393
End page
399
Volume
23
Issue
4
Language
English
OCDE Knowledge area
Oncología
Obstetricia, Ginecología
Subjects
Scopus EID
2-s2.0-84902545429
PubMed ID
Source
Breast
ISSN of the container
09609776
Sponsor(s)
The study was funded by AstraZeneca . AstraZeneca and the steering committee collaborated in the study design, the development of EMs, and collection, analysis, and interpretation of data. Editorial assistance was funded by AstraZeneca. The decision to submit this paper for publication was the lead author's.
CM has received speaker's honoraria and educational grants from AstraZeneca (UK), Novartis (Basel, Switzerland), Pfizer Inc (New York, USA), and Genomic Health Inc (USA). MT has served as a consultant/advisor for AstraZeneca, GlaxoSmithKline, Roche, Eisai and MSD and has received remuneration from AstraZeneca, GlaxoSmithKline, Roche, MSD and Novartis. MM has served as a consultant/advisor for Celgene, Roche, Pierre Fabre and Sanofi-Aventis. RK has served as a consultant/advisor for AstraZeneca. MG has received honoraria from AstraZeneca, Novartis and Sanofi-Aventis, served as a consultant/advisor to AstraZeneca, Novartis, Sanofi-Aventis, Amgen and Roche and received research funding from AstraZeneca, Novartis, Sanofi-Aventis , Amgen , Pfizer and Roche . PN, MM, LA, AF, SN, PT, VD and SB have no conflicts of interest.
We would like to thank the patients, their families and our fellow investigators for their contribution to the CARIATIDE trial, and AstraZeneca for funding and supporting CARIATIDE. We thank Lucy Hurst, from iMed Comms, who provided medical writing support funded by AstraZeneca.
Sources of information:
Directorio de Producción Científica
Scopus